FDA approval for Novartis' Cosentyx to treat moderate-severe hidradenitis suppurativa in adults, offering relief for chronic skin Treatment

FDA approval for Novartis’ Cosentyx to treat moderate-severe hidradenitis suppurativa in adults, offering relief for chronic skin Treatment